Tanios S Bekaii-Saab

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Afsaneh Barzi, Katrina Pedersen, Jeannine S McCune, 2019, The Lancet. Oncology.